<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended SEPTEMBER 30, 1996
------------------------
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to
--------------- ---------------
Commission file number 0-16752
MEDSTONE INTERNATIONAL, INC.
- ------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 66-0439440
- -------------------------------------------------------------------------------
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification No.)
100 COLUMBIA, SUITE 100, ALISO VIEJO, CALIFORNIA 92656-4114
- -------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (714) 448-7700
--------------------------
NOT APPLICABLE
- -------------------------------------------------------------------------------
(Former name, former address and former fiscal year,
if changed, since last report)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports) and (2) has been subject to such
filing requirements for the past 90 days.
Yes X No
----- ------
The number of shares of the Common Stock of the registrant outstanding as of
November 8, 1996 was 5,578,236.
<PAGE> 2
MEDSTONE INTERNATIONAL, INC.
INDEX TO FORM 10-Q
PART I. FINANCIAL INFORMATION
------------------------------
<TABLE>
<CAPTION>
Page No.
--------
<S> <C>
Item 1. Financial Statements:
Condensed Consolidated Balance Sheets September 30, 1996
(Unaudited) and December 31, 1995 3
Condensed Consolidated Statements of Operations (Unaudited)
Three and Nine Months Ended September 30, 1996 and 1995 4
Condensed Consolidated Statement of Stockholders' Equity
(Unaudited) Nine Months Ended September 30, 1996 5
Condensed Consolidated Statements of Cash Flows (Unaudited)
Nine Months ended September 30, 1996 and 1995 6
Notes to Unaudited Condensed Consolidated Financial Statements 7
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations 11
PART II. OTHER INFORMATION
---------------------------
Item 1. Legal Proceedings 15
Item 2. Changes in Securities 15
Item 3. Defaults Upon Senior Securities 15
Item 4. Submission of Matters to a Vote of Security Holders 15
Item 5. Other Information 15
Item 6. Exhibits and Reports on Form 8-K 15
Signatures 16
</TABLE>
<PAGE> 3
MEDSTONE INTERNATIONAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
ASSETS
------
<TABLE>
<CAPTION>
SEPTEMBER 30, DECEMBER 31,
1996 1995
------------- ------------
(Unaudited)
<S> <C> <C>
Current assets:
Cash and equivalents $ 1,401,730 $ 3,108,741
Short-term investments 7,174,310 14,494,717
Accounts receivable, less allowance for
doubtful accounts of $190,000 and
$257,000 in 1996 and 1995, respectively 2,834,076 1,509,407
Inventories 2,295,923 1,764,636
Deferred tax assets 1,583,000 698,000
Prepaid expenses and other current assets 1,334,739 519,542
------------- ------------
Total current assets 16,623,778 22,095,043
Property and equipment, at cost 9,146,322 6,528,930
Less accumulated depreciation and amortization (3,352,336) (3,129,955)
------------- ------------
Net property and equipment 5,793,986 3,398,975
Goodwill, net of accumulated amortization 1,125,708 ---
Other assets, net 22,500 415,838
------------- ------------
$ 23,565,972 $ 25,909,856
============= ============
LIABILITIES AND STOCKHOLDERS' EQUITY
------------------------------------
Current liabilities:
Accounts payable $ 1,698,343 $ 393,542
Accrued expenses 269,121 235,265
Accrued income taxes --- 101,293
Accrued payroll expenses 234,782 206,120
Deferred revenue 958,460 726,260
Customer deposits --- 932
Dividends payable --- 1,966,216
------------- ------------
Total current liabilities 3,160,706 3,629,628
Deferred tax liabilities 123,000 123,000
Minority interest 140,795
Commitments and contingencies (Notes 3 and 8)
Stockholders' equity:
Common stock - $.004 par value, 20,000,000
shares authorized, 5,577,260 and 5,516,528
shares issued and outstanding at
September 30, 1996 and December 31, 1995, respectively 22,160 22,066
Additional paid-in capital 18,647,123 18,555,983
Accumulated earnings 2,109,576 3,710,436
Stock purchase notes receivable (134,800) (134,800)
Unrealized gain/(loss) on short-term investments 2,479 3,543
Treasury stock (55,000 shares at cost, at September
30, 1996 and 0 shares at December 31, 1995) (505,067) ---
------------- ------------
Total stockholders' equity 20,141,471 22,157,228
------------- ------------
$ 38,565,972 $ 25,909,856
============= ============
</TABLE>
See accompanying notes
3
<PAGE> 4
MEDSTONE INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
<TABLE>
<CAPTION>
Three Months Ended Nine Months Ended
September 30, September 30,
1996 1995 1996 1995
------------- ------------- ------------- -------------
<S> <C> <C> <C> <C>
Revenues:
Net equipment sales . . . . . . . . . $ 116,000 $ 1,596,315 $ 1,407,000 $ 3,988,980
Procedures and maintenance fees . . . 4,106,762 3,269,391 10,829,209 8,893,703
Laser catheters . . . . . . . . . . . --- 161,445 --- 749,191
Interest income . . . . . . . . . . . 125,988 256,567 544,403 733,338
------------- -------------- ------------ --------------
Total revenues . . . . . . . . . . . . 4,348,750 5,283,718 12,780,612 14,365,212
Costs and expenses:
Cost of equipment sales . . . . . . . 131,718 686,011 814,142 1,727,487
Costs related to procedures and
maintenance fees . . . . . . . . . . 1,820,863 1,465,835 4,959,570 3,903,646
Cost of laser catheters . . . . . . . --- 88,371 --- 245,433
Research and development . . . . . . . 94,799 186,233 344,964 675,761
Selling . . . . . . . . . . . . . . . 472,480 531,326 1,583,473 1,501,042
General and administrative . . . . . . 471,920 413,249 1,151,471 1,296,257
Settlement costs . . . . . . . . . . . --- --- 5,500,000 ---
Goodwill amortization . . . . . . . . 7,125 --- 14,250 ---
Legal and other expense . . . . . . . 7,500 50,584 803,674 64,189
------------- -------------- ------------ --------------
Total costs and expenses . . . . . . . 3,006,485 3,421,609 15,171,544 9,413,815
------------- -------------- ------------ --------------
Income/(loss) before provision for/
(benefit from) income taxes . . . . 1,342,265 1,862,109 (2,390,932) 4,951,397
Provision for (benefit from) income taxes . 504,000 651,000 (885,000) 1,731,000
Minority interest . . . . . . . . . . . . . 25,879 --- 94,928 ---
------------- -------------- ------------ --------------
Net income (loss) . . . . . . . . . . . . $ 812,386 $ 1,211,109 $ (1,600,860) $ 3,220,397
============= ============== ============ ==============
Earnings per share:
Primary . . . . . . . . . . . . . . . $ .15 $ .22 $ (.29) $ .58
============= ============== ============ ==============
Fully diluted . . . . . . . . . . . . $ .15 $ .21 $ --- $ .56
============= ============== ============ ==============
Number of shares used in the computation of
income per share:
Primary . . . . . . . . . . . . . . . 5,570,771 5,590,330 5,528,594 5,538,913
============= ============== ============ ==============
Fully diluted . . . . . . . . . . . . 5,570,771 5,649,209 --- 5,704,439
============= ============== ============ ==============
</TABLE>
See accompanying notes.
4
<PAGE> 5
MEDSTONE INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
NINE MONTHS ENDED SEPTEMBER 30, 1996
(UNAUDITED)
<TABLE>
<CAPTION>
COMMON STOCK UNREALIZED
---------------------- ADDITIONAL LOSS ON
NUMBER OF PAID-IN ACCUMULATED STOCK PURCHASE SHORT-TERM TREASURY
SHARES AMOUNT CAPITAL EARNINGS NOTE RECEIVABLE INVESTMENTS STOCK TOTAL
---------- ------- ----------- ----------- --------------- ----------- --------- -----------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Balance at
December 31, 1995 5,516,528 $22,066 $18,555,983 $ 3,710,436 $(134,800) $ 3,543 $ --- $22,157,228
Common stock options
exercised 60,732 94 91,140 --- --- --- --- 91,234
Treasury shares
repurchased (55,000) --- --- --- --- --- (505,067) (505,067)
Unrealized loss on
short-term
investments --- --- --- --- --- (1,064) --- (1,064)
Net income (loss) --- --- --- (1,600,860) --- --- --- (1,600,860)
--------- ------- ----------- ----------- --------- ------- --------- -----------
BALANCE AT
SEPTEMBER 30, 1996 5,522,260 $22,160 $18,647,123 $ 2,109,576 $(134,800) $ 2,479 $(505,067) $20,141,471
========= ======= =========== =========== ========= ======= ========= ===========
</TABLE>
See accompanying notes.
5
<PAGE> 6
MEDSTONE INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
NINE MONTHS ENDED SEPTEMBER 30, 1996 AND 1995
(UNAUDITED)
<TABLE>
<CAPTION>
1996 1995
----------- ----------
<S> <C> <C>
Cash flows from operating activities:
Net income . . . . . . . . . . . . . . . . . . . . . . . . . . $(1,600,860) $3,220,397
Adjustments to reconcile net income to net
cash provided (used) by operating activities:
Depreciation and amortization . . . . . . . . . . . . . 846,346 702,251
Minority interest in partnership . . . . . . . . . . . 94,928 ---
Provision for doubtful accounts . . . . . . . . . . . . 30,000 ---
Provision for related party loan . . . . . . . . . . . --- 1,315
Unrealized losses (gains) on short-term
investments . . . . . . . . . . . . . . . . . . . . --- ---
Changes in assets and liabilities:
Accounts receivable . . . . . . . . . . . . . . . . (1,052,014) (728,699)
Inventories . . . . . . . . . . . . . . . . . . . . (750,585) (663,889)
Deferred tax assets . . . . . . . . . . . . . . . . (885,000) ---
Prepaid expenses and other current assets . . . . . (822,532) (108,708)
Accounts payable and accrued expenses . . . . . . . 1,356,936 36,202
Accrued income taxes . . . . . . . . . . . . . . . . (101,293) 85,110
Deferred revenue . . . . . . . . . . . . . . . . . . 233,828 (30,526)
Customer deposits . . . . . . . . . . . . . . . . . --- (40,000)
Other, net . . . . . . . . . . . . . . . . . . . . . (195,690) (131,073)
----------- ------------
Net cash provided by (used in) operating activities . . . . . . (2,845,936) 2,342,380
----------- ------------
Cash flows from investing activities:
Purchase of marketable securities . . . . . . . . . . . . . (11,775,967) (15,471,271)
Sale of marketable securities . . . . . . . . . . . . . . . 19,095,310 14,234,899
Related party loan . . . . . . . . . . . . . . . . . . . . --- 2,450
Purchase of subsidiary . . . . . . . . . . . . . . . . . . (1,350,000) ---
Investment by minority in partnership . . . . . . . . . . . (195,028) ---
Distribution of minority interest . . . . . . . . . . . . . 45,867 ---
Purchase of property and equipment . . . . . . . . . . . . (3,267,424) (1,001,035)
Disposals of property and equipment . . . . . . . . . . . . --- 676,225
----------- ------------
Net cash provided by investing activities . . . . . . . . . 2,552,758 (1,558,732)
----------- ------------
Cash flows from financing activities:
Proceeds from issuance of common stock . . . . . . . . . . 91,234 372,014
Purchase of Treasury Stock . . . . . . . . . . . . . . . . (505,067) ---
Dividends paid . . . . . . . . . . . . . . . . . . . . . . (1,000,000) ---
----------- ------------
Net cash provided by (used in) financing activities . . . . (1,413,833) 372,014
----------- ------------
Net increase (decrease) in cash and cash equivalents . . . . . (1,707,011) 1,155,662
Cash and cash equivalents at beginning of period . . . . . . . 3,108,741 1,261,596
----------- ------------
Cash and cash equivalents at end of period . . . . . . . . . . $ 1,401,730 $ 2,417,258
=========== ============
Supplemental cash flow disclosures:
Cash paid during the period for:
Income taxes . . . . . . . . . . . . . . . . . . . . . . . . $ 520,540 $ 1,645,890
Interest . . . . . . . . . . . . . . . . . . . . . . . . . $ 0 $ 0
</TABLE>
See accompanying notes.
6
<PAGE> 7
MEDSTONE INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 1996
A. ORGANIZATION AND OPERATIONS OF THE COMPANY
Medstone International, Inc. ("Medstone") was incorporated in Delaware
in October 1984. The Company designs, manufactures and markets the Medstone
STSTM Shockwave Therapy System (the "System") for the noninvasive
disintegration of kidney stones in human patients. In addition to sales of the
System, Medstone generates recurring revenue from procedure fees and fee for
service arrangements for use of the System and from repairs and maintenance of
the Systems. The Company, as a manufacturer of capital medical devices, has
been vertically integrating by offering its medical devices directly to
providers on a fee-per-procedure basis. Medstone currently offers mobile
lithotripsy services to customers in the United States on a "wholesale"
fee-per-procedure basis, which consolidated billings are rendered to providers.
Medstone intends to expand efforts to grow this medical service side of its
business.
Northern Nevada Lithotripsy Associates, LLC ("Northern Nevada"), a 60%
joint venture, operates a "retail" lithotripsy operation, which bills patients
or insurers for their services, in contrast to Medstone's fee-for-service
operation, which bills the provider. Medstone acquired its 60% interest in
Northern Nevada for $1.35 million as of April 1, 1996. The operating results
of Northern Nevada are included in the consolidated financial statements of the
Company since April 1, 1996.
United Physicians Resources, Inc. ("UPR") was incorporated in June
1996, to expand the Company's service orientation to the urologist
practitioner. UPR provides billing, practice management, and consulting
services as an additional service line once the initial physician relationship
has been established. UPR purchased the operations of Integrated HealthCare
Systems, Inc. in July 1996 for $30,000. The operating results of UPR are
included in the consolidated financial statements of the Company since its
incorporation.
B. BASIS OF PRESENTATION
In the opinion of the Company's management, the accompanying unaudited
condensed consolidated financial statements include all adjustments (which
consist only of normal recurring adjustments) necessary for a fair presentation
of its consolidated financial position at September 30, 1996 and consolidated
results of operations and cash flows for the periods presented. Certain prior
period balances have been reclassified to conform with current period
presentation. Although the Company believes that the disclosures in these
financial statements are adequate to make the information presented not
misleading, certain information and disclosures normally included in financial
statements prepared in accordance with generally accepted accounting
7
<PAGE> 8
principles have been condensed or omitted and should be read in conjunction
with the Company's audited financial statements included in the Company's 1995
Annual Report on Form 10-K filed with the Securities and Exchange Commission on
March 28, 1996. Results of operations for the nine months ended September 30,
1996 are not necessarily indicative of results to be expected for the full
year.
C. PER SHARE INFORMATION
Per share information is presented in the accompanying consolidated
statements of operations based upon the weighted average number of common and
common equivalent shares outstanding. Common equivalent shares result from the
assumed exercise of outstanding dilutive securities when applying the treasury
stock method. Fully diluted per share information is not presented for periods
in which the effect is antidilutive.
D. INVENTORIES
At September 30, 1996 and December 31, 1995, inventories consisted of
the following:
<TABLE>
<CAPTION>
September 30, 1996 December 31, 1995
------------------ ------------------
<S> <C> <C> <C>
Raw materials . . . . . . . . . . . . $ 1,084,309 $ 1,235,161
Work in process . . . . . . . . . . . 506,914 190,002
Finished goods . . . . . . . . . . . 704,700 339,473
----------------- ------------------
$ 2,295,923 $ 1,764,636
================= ==================
</TABLE>
E. SHORT-TERM INVESTMENTS
The Company adopted Financial Accounting Standards Board Statement No.
115 as of January 1, 1994. The effect of the adoption is that the Company
classifies its entire investment portfolio as available-for-sale. Accordingly,
unrealized holding gains and losses on short-term investments are carried as a
separate component of stockholder's equity.
F. CONTINGENCIES
The Company was a defendant in two related class action lawsuits filed
by two shareholders of the Company alleging that adverse material information
was not disclosed at the time of the initial public offering and in subsequent
periods. On June 20, 1996 the defendants and plaintiffs reached an agreement
whereby a $6 million, non-recapturable settlement fund will be established in
return for dismissal of all claims against the Company, its underwriter and
current and former officers and directors. The Company recorded a one-time,
$5.5 million expense in the second quarter of 1996 to cover its portion of the
settlement fund, with the first half being paid on July 9, 1996 and the second
half paid on August 15, 1996. All funds for the settlement will be remitted by
the Company, with the co-defendants paying their portions to the Company.
8
<PAGE> 9
G. STOCK REPURCHASE PLAN
On March 29, 1996 the Company announced a stock repurchase program of
up to 500,000 shares of its Common Stock. For the quarter ended September 30,
1996, the Company has repurchased no shares. For the nine months ended
September 30, 1996, the Company has repurchased a total of 55,000 shares at a
cost of $505,067.
H. PROFORMA INFORMATION
The following table presents proforma operating results of the
comparative periods in 1996 and 1995 adjusted for the Endocare and Urogen
subsidiaries spun out by the Company on January 1, 1996.
<TABLE>
<CAPTION>
REPORTED ADJUSTMENTS PROFORMA REPORTED ADJUSTMENTS PROFORMA
3-MONTHS FOR 3-MONTHS 3-MONTHS 9-MONTHS FOR 9-MONTHS 9-MONTHS
ENDED ENDOCARE & ENDED ENDED ENDED ENDOCARE & ENDED ENDED
9/30/95 UROGEN 9/30/95 9/30/96 9/30/95 UROGEN 9/30/95 9/30/96
---------- ---------- ---------- ---------- ---------- ---------- ---------- -----------
<S> <C> <C> <C> <C> <C>
Revenues . . . . . . . . . $5,283,718 $ 161,445 $5,122,273 $4,348,750 $14,365,212 $ 749,191 $13,616,021 $12,780,612
Cost of sales . . . . . . . 2,240,217 88,371 2,151,846 1,952,581 5,876,566 274,593 5,601,973 5,773,712
Research & development . . 186,233 79,185 107,048 94,799 675,761 460,471 215,290 344,964
Selling and marketing . . . 531,326 59,863 471,463 472,480 1,501,042 223,793 1,277,249 1,583,473
General and administrative 413,249 76,455 336,794 471,920 1,296,257 243,264 1,502,993 1,151,471
Settlement costs . . . . . --- --- --- 0 --- --- --- 5,500,000
Goodwill amortization . . . --- --- 0 7,125 --- --- --- 14,250
Legal and other expense . . 50,584 --- 50,584 7,580 64,189 --- 64,189 803,674
---------- ---------- ---------- ---------- ----------- ---------- ---------- -----------
Income before taxes . . 1,862,109 (142,429) 2,004,538 1,342,265 4,951,397 (452,930) 5,404,327 (2,390,932)
Income taxes . . . . . . . 651,000 (50,000) 701,000 504,000 1,731,000 (159,000) 1,890,000 (885,000)
Minority interest . . . . . --- --- 0 25,879 --- --- --- 94,928
---------- ---------- ---------- ---------- ----------- ---------- ---------- -----------
Net income (loss) . . . . . $1,211,109 $ (92,429) $1,303,538 $ 812,386 $ 3,220,397 $ (239,930) $3,514,327 $(1,600,860)
========== ========== ========== ========== =========== ========== ========== ===========
Earnings per share:
Primary . . . . . . . . . $ 0.22 $ 0.23 $ 0.15 $ 0.58 $ 0.63 $ (0.29)
========== ========== ========== =========== ========== ===========
Fully diluted . . . . . . $ 0.21 $ 0.23 $ 0.15 $ 0.56 $ 0.62 ---
========== ========== ========== =========== ========== ===========
Number of shares used in
the computation of income
(loss) per share:
Primary . . . . . . . . . 5,590,330 5,590,330 5,570,771 5,538,913 5,538,913 5,528,594
========== ========== ========== =========== ========== ===========
Fully diluted . . . . . . 5,649,209 5,649,209 5,570,771 5,704,439 5,704,439 ---
========== ========== ========== =========== ========== ===========
</TABLE>
9
<PAGE> 10
I. SUBSEQUENT EVENTS
During the third quarter of 1996, the Company entered into a
non-disclosure agreement and performed due diligence on the lithotripsy
operations of Coram Healthcare. The Company's intention was to acquire Coram's
ownership of 13 lithotripsy partnerships, all of which Coram owns at least 50%,
and two wholly-owned subsidiaries, Lithotripsy Management Associates and
ServiceTrends, Inc., whose businesses are partnership management and
lithotripter maintenance services, respectively. The Company agreed in
principal to an acquisition price of $112.5 million, to be financed by a
combination of debt and equity. On October 4, 1996, Coram Healthcare's Board
of Directors asked for a final caveat that their acceptance of the agreement
could be withdrawn throughout the closing period if an offer of higher value
was received. The Company counter-offered without caveat, and Coram's Board of
Directors did not accept, but the Company considered the offer as open ended.
On October 21, 1996 Coram Healthcare announced a definitive merger
agreement with Integrated Health Services, Inc., whereby Coram Healthcare would
become a subsidiary of Integrated Health Services, Inc. Pursuant to that
announcement, Medstone invoked its "breakup fee" clause and is currently
negotiating with Coram to receive full reimbursement of the $1.5 million in
costs incurred by the Company for its due diligence and legal work. For the
quarter and nine months ended September 30, 1996, no expense was recognized in
connection with the acquisition, but all costs were recognized as prepaid
expenses, as management had no indications throughout the period that Coram
Healthcare would not complete the sale of its lithotripsy operations. The
Company will expense any unreimbursed acquisition expenses in the fourth
quarter of 1996.
Also on October 1st and 2nd, the Company liquidated its position in
Endocare, Inc. The average sales price was $5.53 per share, net of
commissions, for the 100,000 shares that were owned by the Company. This will
be recognized as a gain in the fourth quarter of 1996.
10
<PAGE> 11
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
The following discussion and analysis should be read in conjunction
with the Company's audited financial statements and Management's Discussion and
Analysis of Financial Condition and Results of Operations included in the
Company's Annual Report on Form 10-K filed with the Securities and Exchange
Commission on March 28, 1996.
GENERAL
Medstone manufactures, markets and maintains lithotripters, and is
expanding its Fee-for-Service Program to supply lithotripsy equipment to
providers on a per procedure basis. To date, the Company's consolidated
revenues have come primarily from Medstone's lithotripsy business. On February
9, 1996, the Company distributed two stock dividends of 5,516,528 shares of
Endocare, Inc. and UroGen Corp. to its stockholders of record on December 29,
1995. The two dividends represent distribution of all the assets and operations
of the Endocare and Urogen divisions of the Company which were transferred to
the two corporations. Effective with the start of business on January 1, 1996
these two companies are no longer a part of the Medstone International
operations, but are separate, publicly-held companies. Medstone retained only
100,000 shares of each company. On October 2 and 3, 1996, Medstone sold its
100,000 shares of Endocare in open market trading, realizing gross proceeds of
$553,000. (See Notes to Unaudited Condensed Consolidated Financial Statements
Note I - Subsequent Events). On June 17, 1996, the Company completed the
acquisition of 60% in a joint venture, Northern Nevada Lithotripsy Associates,
LLC, for $1.35 million in cash. The acquisition is effective as of April 1,
1996, and the Company's consolidated financials reflect the activity from that
date forward. In June 1996 the Company incorporated United Physicians
Resources, Inc., to expand its service orientation to the urologic practitioner.
In July 1996, UPR purchased the operations of Integrated Healthcare Systems,
Inc. for $30,000, and the consolidated financials reflect the operations of UPR
since inception.
RESULTS OF OPERATIONS
Three Months Ended September 30, 1996 Compared to Three Months Ended
September 30, 1995
The Company recognized revenue of $4.3 million in the third quarter of
1996 or an 18% decrease compared to $5.3 million in the corresponding period of
1995. Equipment revenues decreased by 93 % as no equipment and one equipment
upgrade package was shipped in the third quarter of 1996 compared to shipment of
two equipment units and one upgrade package in the third quarter of 1995. The
recurring revenue stream from laser catheters decreased by $161,000 as the
Company spun off the Endocare, Inc. subsidiary
11
<PAGE> 12
effective January 1, 1996 and no longer records any revenues from the laser
catheter business line. Even though the equipment sales decreased, the revenue
from the Company's maintenance, procedure and fee-for-service activities
increased by 26% in the third quarter of 1996 when compared to the same period
of the prior year due primarily from the 12% increase in the number of patient
treated on the Company's lithotripters in the United States.
Interest income decreased by 51% in the third quarter of 1996 compared
to the same period in 1995 due to decreased market rates and substantially lower
average invested balances as the Company paid it's portion of the settlement
agreement for dismissal of the class action litigation.
Cost of sales on equipment and equipment upgrade sales increased to
113% of sales in the three months ended September 30, 1996, compared to 43% of
sales in the comparable period of the prior year due to increased overhead
expense levels due to a higher production capacity. Recurring revenue costs of
sales decreased to 44% in the three months ended September 30, 1996, compared to
45% in the same period in the prior year due to the increasing revenue base for
the mobile lithotripsy services. Overall cost of sales, as a percentage of
revenue (excluding interest), rose to 46% in the third quarter of 1996 compared
to 45% in the third quarter of 1995.
Research and development costs decreased by 49%, or $92,000 in the
third quarter of 1996 compared to the same quarter of 1995 due to reduced
expenses in developing the Endocare products which occurred in 1995 but was spun
out at the beginning of 1996.
Sales expenses decreased by $59,000 or 11% in the third quarter of 1996
when compared to the same period of 1995 due to the prior year's expenses for
introduction of a new product line in the Endocare subsidiary.
General and administrative expenses increased by $59,000, or 14% in the
third quarter of 1996 when compared to the third quarter of 1995 due to
additional payroll expenses for the United Physicians Resources subsidiary and
the consulting expenses associated with regulatory projects.
Legal and other expenses decreased by $43,000 in the three months ended
September 30, 1996 when compared to the same period of 1995 as legal expenses
are no longer being incurred in connection with the class action securities suit
against the Company and current and former officers.
Provision for income taxes for the third quarter of 1996 represents a
current expense reducing the income tax benefit recorded in the second quarter
which is represented as a deferred tax asset, which the Company fully expects to
recognize with future profits.
12
<PAGE> 13
Nine Months Ended September 30, 1996 Compared to Nine Months Ended
September 30, 1995
The Company recognized revenue of $12.8 million in the nine months
ended September 30,1996 compared to revenue of $14.4 million in the
corresponding period of 1995, or an 11% decrease. Equipment revenues decreased
by 65% as three lithotripsy systems have been shipped in 1996 compared to
shipment of seven lithotripsy systems in 1995, and a decrease in the average
unit sales price. The recurring revenue stream from laser catheters decreased
by $749,000 in the first nine months of 1996 due to the spinout of the Endocare,
Inc. subsidiary. These decreases were partially offset by the increases in the
Company's maintenance, procedure and fee-for-service revenues which rose more
than $1.9 million in the nine months ended September 30,1996 compared to the
same period of the prior year, or an increase of 22%. The number of patients
treated in the first nine months of 1996 increased by 15%, or more than 2,100
patients, over the same period of 1995.
Interest income decreased by 26% in the first nine months of 1996
compared to the same period in 1995 due to lower market rates for investments
and a decrease in average invested balances as the Company paid it's portion of
the settlement agreement for dismissal of the class action litigation along with
devoting more capital for growth of the business.
Cost of sales on equipment and equipment upgrade sales increased to 58%
of sales in the nine months ended September 30, 1996, compared to 43% of sales
in the comparable period of the prior year due to increased overhead expense
levels and a lower average unit selling price. Recurring revenue costs of sales
increased to 46% in the first nine months of 1996, compared to 43% in the same
period in the prior year due to the increased expenses associated with the
Company's expansion of its mobile lithotripsy services. Overall cost of sales,
as a percentage of revenue (excluding interest), rose to 47% in the first nine
months of 1996 compared to 43% in the same period of the prior year.
Research and development costs decreased by $331,000,or 49%, in the
first nine months of 1996 compared to the same period of 1995 due to lower
expenditures on Endocare new product projects which went with the Endocare
spinout.
Sales expenses increased by $82,000 or 5% in the nine months ended
September 30, 1996 when compared to the same period of 1995 due to increased
sales efforts in the expansion of the Company's mobile lithotripsy business.
General and administrative expenses decreased by $145,000, or 11% in
the first nine months of 1996 when compared to the first nine months of 1995 due
to the reduced payroll and legal expenses associated with the Endocare and
Urogen spinouts.
Settlement expense of $5.5 million was recorded in the first nine
months of 1996 to end the class action securities litigation against the Company
and current and former officers. (See Notes to Unaudited Condensed Consolidated
Financial Statements Note F. Contingencies).
13
<PAGE> 14
Legal and other expense increased by $739,000 in the nine months ended
September 30, 1996 when compared to the same period of 1995 as the Company had
negotiated the settlement of the class action securities suit and concurrently
prepared for the scheduled trial date.
LIQUIDITY AND CAPITAL RESOURCES
At September 30, 1996, the Company had cash and short-term investments
of approximately $8.6 million. These funds were generated from operating
activities and from the Company's initial public offering in June 1988, in which
1,150,000 shares of common stock were issued for net proceeds of approximately
$12.9 million. Cash generated from the offering and from operations financed
substantial increases in inventory and capital assets and was used to retire
debt.
In the third quarter of 1996, the Company paid $6 million as required
by the settlement agreement on the class action litigation that the Company has
been part of since October 1989. Management believes that removing this
contingency allows for the best growth potential of the Company, and now the
capital that would have been devoted to trials, appeals and attorney fees can
now be devoted to acquisitions, equipment purchases and working capital needs.
The Company believes that its existing working capital and funds
anticipated to be generated from operations will be sufficient to meet the cash
needs for continuation of its present operations during 1996.
14
<PAGE> 15
MEDSTONE INTERNATIONAL, INC.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
-----------------
None
Item 2. Changes in Securities
---------------------
None
Item 3. Defaults upon Senior Securities
-------------------------------
None
Item 4. Submission of Matters to a Vote of Security Holders
---------------------------------------------------
None
Item 5. Other Information
-----------------
None
Item 6. Exhibits and Reports on Form 8-K
--------------------------------
(a) The following exhibits are included herein:
(11.1) Computation of Per Share Information
(27) Financial Data Schedule
(b) Reports on Form 8-K.
None
15
<PAGE> 16
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MEDSTONE INTERNATIONAL, INC.
A Delaware corporation
Date: November 11, 1996 /s/ MARK SELAWSKI
----------------------------
Mark Selawski
Chief Financial Officer
(Principal financial and
accounting officer)
16
<PAGE> 1
EXHIBIT 11.1
MEDSTONE INTERNATIONAL, INC.
COMPUTATION OF PER SHARE INFORMATION
<TABLE>
<CAPTION>
THREE MONTHS ENDED NINE MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
------------------------------- ---------------------------------
1996 1995 1996 1995
------------- ------------- ------------- --------------
<S> <C> <C> <C> <C>
Earnings:
Net income . . . . . . . . . . . . . . $ 812,386 $ 1,211,109 $ (1,600,860) $ 3,220,397
============== ============= ============= ==============
Computation of primary per share
information:
Shares:
Number of shares outstanding(b) . . 5,521,593 5,208,051 5,528,594 5,185,189
Add effect of outstanding
options and warrants (a) . . . . 49,178 382,279 --- 353,724
-------------- ------------- ------------- --------------
Number of shares outstanding, as
adjusted . . . . . . . . . . . . 5,570,771 5,590,330 5,528,594 5,538,913
============== ============= ============= ==============
Primary earnings per share:
Net income . . . . . . . . . . . . $ .15 $ .22 $ (.29) $ .58
============== ============= ============= ==============
Computation of fully diluted per
share information:
Shares:
Number of shares outstanding
per primary computation . . . . . 5,521,593 5,208,051 5,185,189
Add effect of outstanding options and
warrants (a) . . . . . . . . . . 49,178 441,158 519,250
-------------- ------------- --------------
Number of shares outstanding as
adjusted . . . . . . . . . . . . 5,570,771 5,649,209 5,704,439
============== ============= ==============
Fully diluted earnings per share:
Net income . . . . . . . . . . . . $ .15 $ .21 $ .56
============== ============= ==============
</TABLE>
- -----------------
(a) As determined by the application of the treasury stock method.
(b) Weighted average number of shares outstanding.
17
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-START> JUL-01-1996
<PERIOD-END> SEP-30-1996
<CASH> 1,401,730
<SECURITIES> 7,174,310
<RECEIVABLES> 2,834,076
<ALLOWANCES> 190,000
<INVENTORY> 2,295,923
<CURRENT-ASSETS> 16,623,778
<PP&E> 9,146,322
<DEPRECIATION> 3,352,336
<TOTAL-ASSETS> 23,565,972
<CURRENT-LIABILITIES> 3,160,706
<BONDS> 0
0
0
<COMMON> 22,160
<OTHER-SE> 20,119,311
<TOTAL-LIABILITY-AND-EQUITY> 23,565,972
<SALES> 4,222,762
<TOTAL-REVENUES> 4,328,750
<CGS> 1,952,581
<TOTAL-COSTS> 1,039,119
<OTHER-EXPENSES> 40,584
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> 1,316,386
<INCOME-TAX> 504,000
<INCOME-CONTINUING> 812,386
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 812,386
<EPS-PRIMARY> .15
<EPS-DILUTED> .15
</TABLE>
